Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Pain management

Little evidence to inform pharmacological paediatric migraine prevention, review finds

Looking at trial data involving more than 2,000 young patients with episodic migraine, researchers concluded that further studies were needed to directly compare medicines and psychological treatments, as well as to quantify the placebo effect. 

Child with migraine

Source: Burger / Phone / Science Photo Library

Researchers analysed studies that tested the efficacy of pharmacologic treatments on the prevention of paediatric migraine

There is limited evidence available to support the efficacy of pharmacological treatments in the prevention of paediatric migraines, a systematic review has concluded[1].

The researchers looked at 23 randomised controlled trials, involving 2,217 paediatric and adolescent patients with episodic migraine, and studied the efficacy of prophylactic pharmacologic treatments including antiepileptics, antidepressants, beta blockers, calcium channel blockers, antihypertensive agents and food supplements.

Network meta-analysis found that, in the short term, two treatments — the beta-blocker propranolol and antiepileptic topiramate — had a significant impact on symptoms, such as migraine frequency and number of headache days, compared with placebo (standardised mean difference: 0.60; 95% Confidence Interval [CI], 0.03-1.17 and 0.59; 95% CI, 0.03-1.15, respectively). However, the researchers noted a lack of evidence for long-term treatment in any of the included studies.

Writing in JAMA Pediatrics (10 February 2020), the team said that prophylactic treatment should be very carefully prescribed in children, weighing the benefits against potential harms. They also suggested that the placebo effect could be particularly strong in children and adolescents, compared with adults, which could explain the findings.

“Further studies are needed to determine the best treatment for the prophylaxis of paediatric migraine, especially those that directly compare medicines and psychologic treatments,” they wrote.

“Trials are needed that allow to quantify the placebo effect in paediatric migraine.”

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2020.20207747

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £138.50Buy now
  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50Buy now
  • Clinical Pharmacokinetics

    Clinical Pharmacokinetics

    A practical guide to the use of pharmacokinetic principles in clinical practice. Includes case studies with questions and answers.

    £33.00Buy now
  • Essentials of Economic Evaluation in Healthcare

    Essentials of Economic Evaluation in Healthcare

    An introduction to economic evaluation specific to healthcare, for those with little or no knowledge of economics. Covers cost effectiveness, cost utility and cost benefit analysis.

    £33.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.